<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">R Michael Tuttle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thyroid follicular epithelial-derived cancers include papillary, follicular, and anaplastic cancer. Papillary and follicular cancers are considered differentiated cancers. Follicular thyroid cancer is less common than papillary thyroid cancer. In iodine-sufficient areas, up to 12 percent of all thyroid cancers are follicular cancers, whereas 85 percent are papillary. The molecular pathogenesis, clinical features, diagnosis, and prognostic features of follicular thyroid cancer will be provided here. Papillary thyroid cancer and the management of differentiated thyroid cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a>.)</p><p class="headingAnchor" id="H1109400309"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Follicular thyroid cancer tends to occur in an older population when compared with other differentiated thyroid cancers. Its peak incidence is between ages 40 and 60 years, as compared with papillary thyroid cancer incidence peaking earlier, between the ages of 30 to 50 years. In addition, follicular thyroid cancer is approximately three times more common in women than in men [<a href="#rid1">1</a>]. </p><p>Iodine may also play a role in the epidemiology of follicular thyroid cancer. In iodine-deficient regions of the world, there is a higher prevalence of follicular cancer compared with iodine-sufficient regions. With the introduction of iodine, some studies showed that the incidence of follicular thyroid cancer decreased, while papillary thyroid cancer increased [<a href="#rid2">2,3</a>]. In a report from Poland, rates of follicular thyroid cancer actually decreased between 1982 and 2012, a time during which rates of papillary thyroid cancer were increasing [<a href="#rid4">4</a>]. In an analysis of 90,803 incident cases of thyroid cancer from the SEER 9 registry data (1975 to 2016), the incidence of follicular thyroid cancer was fairly stable during the study period [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Incidence'</a>.)</p><p class="headingAnchor" id="H4202641897"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for follicular thyroid cancer are similar to those for papillary thyroid cancer and include a history of radiation exposure during childhood, a history of thyroid cancer in a first-degree relative, or a family history of a thyroid cancer syndrome. Radiation exposure of the thyroid during childhood is the most clearly defined environmental factor associated with benign and malignant thyroid tumors. (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">MOLECULAR PATHOGENESIS</span><span class="headingEndMark"> — </span>Most follicular thyroid cancers are probably of monoclonal origin. In addition, oncogene activation is common. (See  <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer", section on 'Follicular thyroid cancer'</a>.)</p><p>Factors associated with follicular thyroid cancer include:</p><p class="headingAnchor" id="H4"><span class="h2">RAS mutations</span><span class="headingEndMark"> — </span>Point mutations of the <em>RAS</em> oncogene are seen in approximately 40 percent of follicular cancers [<a href="#rid6">6</a>]. These mutations (<em>N-RAS</em>, <em>H-RAS,</em> and <em>K-RAS</em>, in order of decreasing frequency) occur more commonly in follicular thyroid cancers than in follicular adenomas [<a href="#rid7">7,8</a>]. <em>RAS</em> mutations are not specific to follicular thyroid cancer; they also account for a small portion of papillary thyroid cancers, particularly the follicular-variant papillary thyroid cancer [<a href="#rid8">8</a>].</p><p><em>RAS</em> mutations in follicular thyroid cancer appear to be associated with more aggressive cancers and higher mortality [<a href="#rid9">9</a>]. In addition, <em>RAS</em> mutations may be found in poorly differentiated and anaplastic thyroid cancers [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h2">PAX8-PPAR gamma 1</span><span class="headingEndMark"> — </span>PAX8-PPAR gamma 1 is a gene rearrangement seen in follicular adenomas and cancers. This fusion protein of a thyroid-specific transcription factor (PAX8) and a nuclear receptor, peroxisome proliferator-activated receptor (PPAR) gamma, is associated with approximately 10 percent of follicular adenomas and 41 percent of follicular cancers [<a href="#rid10">10</a>]. This fusion protein may help distinguish follicular adenoma from follicular carcinoma [<a href="#rid11">11</a>]. It is thought that PAX8-PPAR gamma 1 induces a negative effect on thiazolidinedione activation by PPAR gamma, leading to loss of growth inhibitory controls [<a href="#rid12">12</a>].</p><p>The fact that follicular thyroid cancer contains either <em>RAS</em> mutations or a PAX8-PPAR gamma 1 rearrangement, but not both, indicates that similar, yet distinct molecular events may originate with these two oncogenes.</p><p class="headingAnchor" id="H7"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other factors, such as p53, c-myc, c-fos, telomerase reverse transcriptase (TERT) promoter mutations, and thyroid-stimulating hormone (TSH) receptor mutations, have also been implicated [<a href="#rid13">13,14</a>]. Unlike papillary thyroid cancer, follicular thyroid cancer is rarely associated with <em>RET</em>/<em>PTC</em> mutations or <em>BRAF</em> mutations [<a href="#rid15">15,16</a>].</p><p>Follicular thyroid cancer can be seen as part of familial neoplastic syndromes, such as Cowden syndrome (PTEN), Carney complex type 1 (PRKAR1alpha), or Werner syndrome (WRN). (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Thyroid'</a> and  <a class="medical medical_review" href="/z/d/html/100662.html" rel="external">"Carney complex", section on 'Endocrine tumors'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H595054907"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Patients with follicular thyroid cancer typically present with a thyroid nodule. Thyroid nodules come to clinical attention when noted by the patient, as an incidental finding during routine physical examination or during a radiologic procedure, such as carotid ultrasonography, neck computed tomography (CT), or positron emission tomography (PET) scanning. (See  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H4102579329"><span class="h2">Histology</span><span class="headingEndMark"> — </span>The histology ranges from normal, well-differentiated epithelium with follicular development and colloid (findings associated with a good prognosis) to poorly differentiated with solid growth, absence of follicles, marked nuclear atypia, and extensive vascular and/or capsular invasion (characteristics that are associated with a worse prognosis)  (<a class="graphic graphic_picture graphicRef65775" href="/z/d/graphic/65775.html" rel="external">picture 1</a>) [<a href="#rid17">17</a>] (see <a class="local">'Prognostic features'</a> below). Typically, the microfollicular architecture is uniform with an invariant collection of cuboidal cells lining the follicles. In addition, features consistent with papillary cancer, such as psammoma bodies and nuclear changes (ground-glass appearance, longitudinal grooves, nuclear overlapping, and inclusions), should be absent. Microscopically, the diagnosis of follicular cancer requires distinguishing adenoma from cancer through identification of tumor extension through the tumor capsule and/or vascular invasion  (<a class="graphic graphic_picture graphicRef75526" href="/z/d/graphic/75526.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef51148" href="/z/d/graphic/51148.html" rel="external">picture 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follicular thyroid cancer</strong> – Well differentiated follicular thyroid cancers are classified into one of the three following groups based on the type and extent of invasion [<a href="#rid17">17-21</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Minimally invasive follicular thyroid cancer," which includes tumors with invasion only of the capsule of the tumor without vascular invasion (American Thyroid Association [ATA] low-risk tumor)  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Encapsulated angioinvasive follicular thyroid cancer," which includes encapsulated tumors with any evidence of vascular invasion. We further risk-stratify angioinvasive encapsulated follicular thyroid cancers based on the number of vessels involved as either ATA low risk (&lt;4 foci of vascular invasion, often referred to as limited or minimal vascular invasion) or ATA high risk (≥4 foci of vascular invasion, often referred to as extensive vascular invasion)  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Widely invasive follicular thyroid cancer," which includes tumors with clinically obvious gross invasion of the thyroid gland and extrathyroidal soft tissues, usually with extensive vascular invasion often involving extrathyroidal vessels. It is important to note that vascular invasion alone, even if ≥4 foci, does not provide sufficient evidence to classify the tumor as widely invasive follicular thyroid cancer in the absence of gross invasion.</p><p></p><p class="bulletIndent1">Uncommon histologic variants of follicular thyroid cancer are rarely seen (eg, clear cell variant, signet-ring cell type, follicular thyroid cancer with glomeruloid pattern, and spindle cell follicular thyroid cancer) [<a href="#rid22">22</a>]. It is unclear whether the biological outcomes of these subtypes differ substantially from classic follicular thyroid cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oncocytic carcinoma of the thyroid</strong> – Historically, oncocytic carcinoma of the thyroid (previously called Hürthle cell cancer) was considered to be a variant of follicular thyroid cancer. However, recent clinical and molecular studies clearly indicate that oncocytic carcinoma of the thyroid is a distinct tumor type [<a href="#rid22">22</a>]. Clinically, oncocytic carcinoma of the thyroid often has a similar clinical presentation to follicular thyroid cancer (usually asymptomatic thyroid nodule in older patients) and a similar pattern of distant metastases (lung, bone, brain). Histologically, it is characterized by the presence of a cell population of "oncocytes," mostly eosinophilic oxyphilic cells with abundant cytoplasm, closely packed mitochondria, and round oval nuclei with prominent nucleoli  (<a class="graphic graphic_picture graphicRef80758" href="/z/d/graphic/80758.html" rel="external">picture 4</a>) [<a href="#rid23">23</a>]. Unlike follicular thyroid cancer, oncocytic carcinoma of the thyroid has more of a propensity to spread to cervical lymph nodes [<a href="#rid24">24</a>]. While metastatic lesions in follicular thyroid cancer often concentrate radioiodine, oncocytic carcinoma of the thyroid metastatic foci are often radioiodine refractory. Furthermore, the molecular profile of oncocytic carcinoma of the thyroid is very distinct from follicular thyroid cancer (see  <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer", section on 'Follicular thyroid cancer'</a>). Thus, oncocytic carcinoma of the thyroid is now considered a distinct form of follicular cell-derived thyroid cancer.</p><p></p><p class="headingAnchor" id="H1945903"><span class="h2">Lymph node involvement</span><span class="headingEndMark"> — </span>Follicular tumors are more typically uninodular when compared with papillary thyroid cancer. While vascular invasion is frequent with follicular cancer, spread to lymph nodes is uncommon, occurring in only 8 to 13 percent of cases [<a href="#rid25">25</a>]. However, lymph node involvement is more common in oncocytic carcinoma of the thyroid [<a href="#rid26">26</a>]. In contrast, lymph node involvement is very common in papillary thyroid cancer. (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Histology'</a>.)</p><p class="headingAnchor" id="H1945909"><span class="h2">Metastases</span><span class="headingEndMark"> — </span>Follicular thyroid cancer typically spreads via hematogenous dissemination. Distant metastases occur in 10 to 15 percent of patients with follicular cancer, even in those with small primary tumors, although tumors &lt;2 cm in size have not been associated with metastatic disease [<a href="#rid27">27</a>]. Common sites of distant metastases are bone (with lytic lesions) and lung and, less commonly, the brain, liver, bladder, and skin  (<a class="graphic graphic_diagnosticimage graphicRef50158" href="/z/d/graphic/50158.html" rel="external">image 1</a>) [<a href="#rid26">26</a>].</p><p>Although rare, functional thyroid cancer metastases can cause symptomatic hyperthyroidism. Nearly all patients reported have had widely metastatic follicular thyroid cancer, often involving bone among other organs [<a href="#rid28">28,29</a>]. The majority of patients with functional thyroid cancer metastases have had high serum triiodothyronine (T3) but normal thyroxine (T4) concentrations (T3-thyrotoxicosis). The mechanism is high activity of the type 1 and type 2 iodothyronine deiodinases in tumor tissues, ie, exogenously administered <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> is converted to T3 [<a href="#rid30">30</a>]. A few of these patients have also had serum TSH receptor-stimulating antibodies, the presence of which would be expected to increase the hormonal synthetic capacity of the cancer [<a href="#rid29">29</a>].</p><p>The functional metastases can be identified by whole-body radioiodine imaging. Treatment may require a variety of approaches including thionamides, radioiodine, surgery, or external radiotherapy. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a>.)</p><p class="headingAnchor" id="H2714680978"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The actual diagnosis of follicular thyroid cancer requires histologic evaluation of the thyroid after surgery and the identification of tumor capsule and/or vascular invasion.</p><p>Although fine-needle aspiration (FNA) is the initial diagnostic tool of choice in evaluating thyroid nodules, exceeding the utility of physical exam, laboratory evaluation, and imaging tests, FNA biopsy cannot diagnose follicular thyroid cancer (unlike papillary thyroid cancer), because it cannot distinguish between follicular adenomas and cancers. These FNA specimens are often indeterminant lesions, categorized as follicular neoplasms or atypia of undetermined significance (AUS), with epithelial cells arranged in a pattern of microfollicles, scant or absent colloid, and few macrophages. (See  <a class="medical medical_review" href="/z/d/html/7823.html" rel="external">"Atlas of thyroid cytopathology", section on 'Follicular neoplasm'</a>.)</p><p>For patients with initial cytologic results showing follicular neoplasm or repeat aspirates confirming a reading of AUS, further evaluation is necessary. Evaluation may include molecular testing of FNA aspirates or, if no such testing is not available, diagnostic lobectomy. Molecular testing of FNA aspirates can reduce but not eliminate the number of patients who require diagnostic surgery. The use of molecular markers in the evaluation of thyroid nodules is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults", section on 'Molecular markers'</a> and  <a class="medical medical_review" href="/z/d/html/7823.html" rel="external">"Atlas of thyroid cytopathology", section on 'Follicular neoplasm'</a> and  <a class="medical medical_review" href="/z/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults", section on 'Evaluation and management'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">PROGNOSTIC FEATURES</span><span class="headingEndMark"> — </span>The prognosis for differentiated thyroid cancers is best for young patients who have minimal capsular and vascular invasion. Given that follicular cancer typically occurs in older patients, it is more commonly associated with an aggressive clinical course, distant metastases, and higher mortality than papillary thyroid cancer. Women may have a better prognosis than men [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2954880569"><span class="h2">Stage</span><span class="headingEndMark"> — </span>Postoperative staging, based upon the clinicopathologic features of each case, is important for providing prognostic information. We use both the tumor, node, metastasis (TNM) classification scheme for prediction of disease-specific mortality  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>) and the American Thyroid Association (ATA) risk of recurrence staging system for initial assessment of risk of recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). While initial risk stratification can be used to guide initial therapeutic and diagnostic follow-up strategy decisions, it is important to recognize that initial risk estimates may need to change as new data are accumulated during follow-up for each individual patient. Staging is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Age</span><span class="headingEndMark"> — </span>Age is a significant prognostic factor [<a href="#rid26">26,31</a>]. The 10-year survival rate for patients with differentiated thyroid cancer is over 95 percent if the patient is less than 40 years of age [<a href="#rid32">32</a>]. Patients in whom the diagnosis occurs between ages 40 to 59 years have an 80 percent 10-year survival rate.</p><p class="headingAnchor" id="H15"><span class="h2">Tumor characteristics</span><span class="headingEndMark"> — </span>Other prognostic factors associated with higher mortality include:</p><p class="bulletIndent1"><span class="glyph">●</span>Distant metastasis – Up to 25 percent of cases of follicular thyroid cancer may include distant metastasis [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vascular invasion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Capsular extension – Minimally invasive follicular cancer (MIFC) has been associated with good survival and is considered low risk when compared with widely invasive follicular cancer (WIFC). WIFC typically occurs in an older population, with larger tumor size, invasion into the thyroid, and distant metastases. When both extensive capsule and vascular invasion are present, distant metastases are present in more than 50 percent of cases [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor size – Unlike papillary thyroid cancer, no "occult" follicular thyroid cancer or microcarcinoma with minimal mortality risk exists. Smaller tumors should be examined using the same risk categories as used with larger tumors. There is a linear relationship when comparing the size of the tumor with cancer mortality and recurrence [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early recurrence, which more commonly occurs in older male patients [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oncocytic carcinoma of the thyroid may be associated with poorer prognosis than follicular cancer, perhaps related to the tumor's poor affinity for taking up radioiodine. In one study, the 10-year, disease-free interval was 75 percent for follicular cancer and 41 percent for oncocytic carcinoma of the thyroid [<a href="#rid35">35</a>]. Oncocytic carcinoma of the thyroid has been shown to have an increased recurrence rate in local lymph nodes [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insular cancer, a poorly differentiated follicular thyroid cancer variant, also carries a poor prognosis as it is commonly found to be an invasive tumor with extensive regional and distant metastasis [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H16"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Papillary and follicular cancers are treated similarly despite numerous biologic differences [<a href="#rid37">37</a>]. The optimum treatment, however, remains controversial as there is a lack of randomized controlled trials comparing various modalities in follicular thyroid cancer. Therefore, treatment strategies for follicular thyroid cancer are based primarily upon indirect evidence from papillary thyroid cancer data. Treatment should be based upon risk assessment of each individual patient. An important part of treatment is continued reassessment of the risks of recurrence and mortality as new information is gathered during follow-up evaluations. The management of differentiated thyroid cancer is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery is the primary mode of therapy for patients with differentiated thyroid cancer. Preoperative ultrasound is important for planning the surgical procedure. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Surgical management'</a> and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Approach to thyroidectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative management includes treatment with thyroid hormone suppressive therapy (most patients) and radioiodine (high-risk and selected intermediate-risk patients). Postoperative management depends upon the risk of recurrence/persistent disease  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Subsequent management based on risk classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other, less common treatment modalities for follicular thyroid cancer include external beam radiotherapy (EBRT) and chemotherapy. EBRT is typically reserved for older patients with nonresectable metastatic disease that does not take up iodine or has been resistant to therapy with radioiodine. Pain relief for bony lesions and spinal cord compression may also indicate a need for EBRT. (See  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy", section on 'Indications for EBRT'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with metastatic differentiated thyroid cancer (papillary or follicular) that persists despite radioiodine, TSH-suppressive thyroid hormone therapy, and external radiotherapy, treatment options include observation, kinase inhibitors that primarily target angiogenesis, and traditional cytotoxic chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/2191.html" rel="external">"Differentiated thyroid cancer refractory to standard treatment: Systemic therapy"</a>.)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Monitoring patients thought to be disease free for recurrence is an important goal for long-term therapy. Methods of evaluation for recurrence depend upon initial therapy and risk of recurrence, and they should be individualized for each patient. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Monitoring response to therapy'</a>.)</p><p class="headingAnchor" id="H21949266"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82979.html" rel="external">"Patient education: Thyroid cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Follicular thyroid cancer, a well-differentiated tumor of thyroid epithelium, is the second most common type of thyroid cancer after papillary thyroid cancer. It is more common in iodine-deficient areas and tends to occur in an older population when compared with papillary thyroid cancer. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular pathogenesis</strong> – Most follicular thyroid cancers contain either <em>RAS</em> mutations or a PAX8-PPAR gamma 1 rearrangement but not both, indicating that similar yet distinct molecular events may originate with these two oncogenes. (See <a class="local">'Molecular pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and diagnosis</strong> – Patients with follicular thyroid cancer typically present with a thyroid nodule. Fine-needle aspiration (FNA) biopsy alone cannot distinguish between follicular adenomas and cancers. These FNA specimens are often indeterminant lesions, categorized as follicular neoplasms or atypia of undetermined significance (AUS). The actual diagnosis of follicular thyroid cancer requires histologic evaluation of the thyroid after surgery and the identification of tumor capsule and/or vascular invasion. (See <a class="local">'Clinical features'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic features</strong> – Important prognostic features include stage, age, and tumor characteristics (tumor size, vascular invasion, capsular extension, histologic grade, Hürthle cell or insular variant, and distant metastases). (See <a class="local">'Prognostic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment options available for follicular thyroid cancer are the same as for all differentiated thyroid cancers. The management of differentiated thyroid cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a> and <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H2858137412"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stephanie L Lee, MD, PhD, and Sonia Ananthakrishnan, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">https://seer.cancer.gov/statfacts/html/thyro.html (Accessed on March 08, 2017).</li><li><a class="nounderline abstract_t">Pettersson B, Adami HO, Wilander E, Coleman MP. Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. Int J Cancer 1991; 48:28.</a></li><li><a class="nounderline abstract_t">Harach HR, Escalante DA, Onativia A, et al. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol (Copenh) 1985; 108:55.</a></li><li><a class="nounderline abstract_t">Konturek A, Barczyński M, Stopa M, Nowak W. Trends in Prevalence of Thyroid Cancer Over Three Decades: A Retrospective Cohort Study of 17,526 Surgical Patients. World J Surg 2016; 40:538.</a></li><li><a class="nounderline abstract_t">Pereira M, Williams VL, Hallanger Johnson J, Valderrabano P. Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations. Thyroid 2020; 30:1132.</a></li><li><a class="nounderline abstract_t">Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 1993; 4:615.</a></li><li><a class="nounderline abstract_t">Lemoine NR, Mayall ES, Wyllie FS, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988; 48:4459.</a></li><li><a class="nounderline abstract_t">Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120:71.</a></li><li><a class="nounderline abstract_t">Garcia-Rostan G, Zhao H, Camp RL, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21:3226.</a></li><li class="breakAll">Fagin JA. Molecular genetics of tumors of thyroid follicular cells. In: Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2005. p.909.</li><li><a class="nounderline abstract_t">Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002; 87:3947.</a></li><li><a class="nounderline abstract_t">Martelli ML, Iuliano R, Le Pera I, et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002; 87:4728.</a></li><li><a class="nounderline abstract_t">Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004; 15:319.</a></li><li><a class="nounderline abstract_t">Führer D, Tannapfel A, Sabri O, et al. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocr Relat Cancer 2003; 10:591.</a></li><li><a class="nounderline abstract_t">Cerilli LA, Mills SE, Rumpel CA, et al. Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol 2002; 118:186.</a></li><li><a class="nounderline abstract_t">Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245.</a></li><li><a class="nounderline abstract_t">Collini P, Sampietro G, Rosai J, Pilotti S. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch 2003; 442:71.</a></li><li><a class="nounderline abstract_t">D'Avanzo A, Treseler P, Ituarte PH, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004; 100:1123.</a></li><li><a class="nounderline abstract_t">Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001; 11:637.</a></li><li><a class="nounderline abstract_t">Baloch ZW, LiVolsi VA. Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology. Endocr Pathol 2014; 25:12.</a></li><li class="breakAll">WHO Classification of Tumours Editorial Board. WHO Classification of Endocrine and Neuroendocrine Tumours, 5th ed, International Agency for Research on Cancer, 2022.</li><li class="breakAll">Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 4th ed. Lyon: IARC; 2017.</li><li><a class="nounderline abstract_t">Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009; 19:1159.</a></li><li><a class="nounderline abstract_t">Bishop JA, Wu G, Tufano RP, Westra WH. Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland. Thyroid 2012; 22:690.</a></li><li class="breakAll">Rosai J, Carcangiu ML, De Lellis RA. Tumors of the thyroid gland. In: Atlas of tumor pathology, Armed Forces Institute of Pathology, Washington, DC 1992. Vol Fascicle 5.</li><li><a class="nounderline abstract_t">Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am 1995; 24:761.</a></li><li><a class="nounderline abstract_t">Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103:2269.</a></li><li><a class="nounderline abstract_t">Bowden WD, Jones RE. Thyrotoxicosis associated with distant metastatic follicular carcinoma of the thyroid. South Med J 1986; 79:483.</a></li><li><a class="nounderline abstract_t">Kasagi K, Takeuchi R, Miyamoto S, et al. Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol (Oxf) 1994; 40:429.</a></li><li><a class="nounderline abstract_t">Miyauchi A, Takamura Y, Ito Y, et al. 3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab 2008; 93:2239.</a></li><li><a class="nounderline abstract_t">Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.</a></li><li class="breakAll">Ries LAG, Eisner MP, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute. Bethesda, MD, 2004. http://seer.cancer.gov/csr/1975_2001/ (Accessed on October 22, 2005).</li><li class="breakAll">Mazzaferri EL. Thyroid carcinoma: Papillary and follicular. In: Endocrine Tumors, Mazzaferri EL, Samaan NA (Eds), Blackwell Scientific, Cambridge, MA 1993. p.278.</li><li><a class="nounderline abstract_t">Lin JD, Hsueh C, Chao TC. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 2009; 19:1053.</a></li><li><a class="nounderline abstract_t">Kushchayeva Y, Duh QY, Kebebew E, et al. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 2008; 195:457.</a></li><li><a class="nounderline abstract_t">Lai HW, Lee CH, Chen JY, et al. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy. J Am Coll Surg 2006; 203:715.</a></li><li><a class="nounderline abstract_t">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</a></li></ol></div><div id="topicVersionRevision">Topic 7867 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://seer.cancer.gov/statfacts/html/thyro.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : https://seer.cancer.gov/statfacts/html/thyro.html (Accessed on March 08, 2017).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019455" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969810" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26560150" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in Prevalence of Thyroid Cancer Over Three Decades: A Retrospective Cohort Study of 17,526 Surgical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32098591" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8286433" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The role of p21ras in receptor tyrosine kinase signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3293774" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Activated ras oncogenes in human thyroid cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12866375" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12947056" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12947056" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161538" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364466" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681856" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14713269" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12162676" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Interpretation of RET immunostaining in follicular lesions of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947100" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : BRAF mutation in thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12536317" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022277" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Follicular thyroid carcinoma: histology and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11484892" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24464744" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24464744" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24464744" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19888858" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Bethesda System for Reporting Thyroid Cytopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22524498" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22524498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608779" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15856429" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3704707" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Thyrotoxicosis associated with distant metastatic follicular carcinoma of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8187309" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397985" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977430" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977430" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977430" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772423" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070728" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084334" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
